Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
01 Febrero 2024 - 3:30PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that Ron Peck, M.D., Chief Medical
Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate
and Business Development will participate in a fireside chat at the
6th Annual Guggenheim Biotechnology Conference on Wednesday,
February 7 at 10:30 a.m. ET in New York.
A live audio webcast of the presentation will be available here
and under “Events and Presentations” of the Investors and Media
section of the Company’s website.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC
protein degraders against validated and “undruggable” targets, the
company has three investigational clinical-stage programs:
vepdegestrant (ARV-471) for the treatment of patients with locally
advanced or metastatic ER+/HER2- breast cancer; and ARV-766 and
bavdegalutamide for the treatment of men with metastatic
castration-resistant prostate cancer. For more information,
visit www.arvinas.com.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kathleen Murphy+1 (760)
622-3771Kathleen.Murphy@arvinas.com
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024